Literature DB >> 15603542

Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology.

Alison E M Vickers1, Kristine Rose, Robyn Fisher, Muriel Saulnier, Pritam Sahota, Philip Bentley.   

Abstract

Kidney slices represent an in vitro model that has the cellular complexity of in vivo tissue to provide insights into mechanisms of organ injury, as shown in this study with the model nephrotoxicant cisplatin. Cell pathways altered by cisplatin exposure are assessed by gene expression analysis, cell function, and morphology in human and rat kidney slices in comparison to rat kidney from an in vivo study. The acute nephrosis of the tubular epithelium induced by cisplatin in vivo was reproduced in both human and rat kidney slices, while the glomerulus appeared resistant even at high concentrations. Kidney gene expression changes of in vivo and in vitro samples were indicative of transcription, DNA damage, cell cycle, proliferation, and apoptosis that are in agreement with the mechanism of cisplatin causing DNA damage, growth arrest, and apoptosis; while genes indicative of protein damage, the disruption of transport and calcium homeostasis, cellular metabolism, and oxidative stress are pathways linked with cisplatin binding to various cellular proteins and macromolecules. Both concentration and time-dependent gene expression changes evident in the in vitro model preceded a change in tissue morphology. Functional assays confirming cell dysfunction and increased apoptosis revealed the rat kidney to be more sensitive to the effects of cisplatin than human kidney as demonstrated by significant decreases in slice ATP and GSH levels, significant increases in caspase 9 and 3 activity, p53 protein levels, and increased DNA laddering. The regional markers of proximal and distal tubular injury, alpha- and pi-glutathione S-transferases, were shown for the human kidney slices to be significantly increased by cisplatin. In this study, cisplatin-induced nephrotoxicity was demonstrated morphologically in rat and human kidney slices, and the associated gene expression and functional changes characterized the cellular pathways involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15603542     DOI: 10.1080/01926230490508821

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  38 in total

1.  In vivo inhibition of renal heme oxygenase with an imidazole-dioxolane inhibitor.

Authors:  Eva Csongradi; Trinity Vera; John M Rimoldi; Rama S V Gadepalli; David E Stec
Journal:  Pharmacol Res       Date:  2010-03-23       Impact factor: 7.658

2.  Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy.

Authors:  Günter Oberdörster; Andrew Maynard; Ken Donaldson; Vincent Castranova; Julie Fitzpatrick; Kevin Ausman; Janet Carter; Barbara Karn; Wolfgang Kreyling; David Lai; Stephen Olin; Nancy Monteiro-Riviere; David Warheit; Hong Yang
Journal:  Part Fibre Toxicol       Date:  2005-10-06       Impact factor: 9.400

3.  Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands.

Authors:  Natalia Estrada-Ortiz; Elena Lopez-Gonzales; Ben Woods; Stefan Stürup; Inge A M de Graaf; Geny M M Groothuis; Angela Casini
Journal:  Toxicol Res (Camb)       Date:  2019-09-20       Impact factor: 3.524

4.  cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac.

Authors:  Yu Qin; Geurt Stokman; Kuan Yan; Sreenivasa Ramaiahgari; Fons Verbeek; Marjo de Graauw; Bob van de Water; Leo S Price
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 5.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

6.  Experimental considerations on the cytotoxicity of nanoparticles.

Authors:  Bokyung Kong; Ji Hyun Seog; Lauren M Graham; Sang Bok Lee
Journal:  Nanomedicine (Lond)       Date:  2011-07       Impact factor: 5.307

7.  Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.

Authors:  Rodney J Hunter; Makala B Pace; Kimberly A Burns; Catherine C Burke; Deborah A Gonzales; Nicki F Webb; Charles F Levenback; Anuja Jhingran; Crystal Parker; Mark F Munsell; Judith A Smith
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

8.  Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.

Authors:  Yoshitaka Saito; Masaki Kobayashi; Takehiro Yamada; Kumiko Kasashi; Rio Honma; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Ken Iseki
Journal:  Support Care Cancer       Date:  2016-10-03       Impact factor: 3.603

Review 9.  Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy.

Authors:  Siddesh Jaiman; Arun Kumar Sharma; Kulwant Singh; Deepa Khanna
Journal:  Eur J Clin Pharmacol       Date:  2013-08-09       Impact factor: 2.953

Review 10.  Patient-derived tumour models for personalized therapeutics in urological cancers.

Authors:  Arjanneke F van de Merbel; Geertje van der Horst; Gabri van der Pluijm
Journal:  Nat Rev Urol       Date:  2020-11-10       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.